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Abstract	Patients	 with	 chronic	 kidney	 disease	 (CKD)	 have	 an	 enhanced	 risk	 of	cardiovascular	(CV)	morbidity	and	mortality	when	compared	to	age	and	gender-matched	 individuals	 with	 normal	 kidney	 function.	 Trimethlyamine-N-oxide	(TMAO)	is	a	gut-derived	amine	oxide	that	has	been	implicated	in	the	causation	of	cardiovascular	diseases.	Plasma	TMAO	is	cleared	by	the	kidney	and	TMAO	levels	are	 elevated	 in	 CKD.	 Experimental	 studies	 have	 identified	 pathogenic	mechanisms	by	which	TMAO	may	contribute	to	cardiovascular	disease	through	dysregulation	 of	 lipid	 metabolism,	 enhanced	 macrophage	 foam	 cell	 formation	and	platelet	dysfunction.	Safe	and	well	tolerated	therapeutic	interventions	such	as	pre-	and	probiotics,	which	modify	the	gut	microbiome,	offer	the	opportunity	for	 interventional	studies.	This	review	examines	the	pathogenicity	of	TMAO,	 its	value	as	a	biomarker	and	 its	potential	 as	a	 therapeutic	 target	 in	 the	 context	of	CKD.		
Cardiovascular	disease	in	CKD	–	Unexplained	risk	Patients	 with	 chronic	 kidney	 disease	 (CKD)	 have	 an	 enhanced	 risk	 of	cardiovascular	(CV)	morbidity	and	mortality	when	compared	to	age	and	gender-matched	 individuals	 with	 normal	 kidney	 function.1	 Advanced	 kidney	 disease	(stage	G5A3;	 estimated	 glomerular	 filtration	 rate	 (eGFR)	 <15	mL/min/1.73m2,	albumin:creatinine	 ratio	 >30	mg/mM)	 carries	 an	 8-fold	 increased	 adjusted	 CV	mortality	risk	when	compared	to	subjects	with	no	kidney	disease.	2	Traditional	CV	risk	factors	such	as	hypertension	and	dyslipidaemia	are	frequently	present	in	
CKD,	but	 they	do	not	provide	 the	same	predictive	value	as	 for	 individuals	with	normal	kidney	function.	3,4	This	could	be	because	different	risk	factors	contribute	to	CV	disease	pathogenesis	 in	CKD,	 for	 example	hyperphosphataemia,	 anaemia	and	other	metabolic	derangements	related	 to	a	 “uraemic	milieu.”	Several	novel	risk	markers	have	been	identified	in	CKD	but	none	have	been	causally	linked	to	CV	 disease	 pathogenesis	 in	 interventional	 studies.	 For	 example,	 promising	interventions	 designed	 to	 ameliorate	 abnormal	 bone-mineral	 metabolism	 in	patients	 receiving	 hemodialysis	 such	 as	 non-calcium-based	 oral	 phosphate	binders	 5	 and	 calcimimetics,	 6	 failed	 to	 reduce	mortality	 or	 CV	 events	 in	 large	randomized	trials	(although	secondary	analyses	and	trends	suggested	potential	benefit	 in	 some	 populations).	 Indeed,	 with	 the	 exception	 of	 combined	statin/ezetimibe	lipid-lowering	therapy,	7	no	interventions	have	been	proven	to	reduce	CV	risk	in	large	scale	randomized	controlled	trials	specifically	recruiting	CKD	patients.		
	
The	gut	microbiome	in	health	and	disease	The	human	gastrointestinal	 tract	 is	 colonized	by	approximately	10-100	 trillion	(or	 1014)	 microbes,	 outnumbering	 the	 host’s	 own	 somatic	 and	 germ	 cell	population	by	a	factor	of	ten.	8	During	health,	this	gut	microbiome	functions	both	as	a	 living	barrier	against	 ingested	noxious	substances	and	 liberates	otherwise	inaccessible	nutrients	for	systemic	absorption.	Subpopulations	of	gut	microbiota	vary	widely	between	individuals	and	can	have	a	measureable	impact	upon	whole	body	nutrition,	metabolism	and	immune	function.	8	Potentially	toxic	metabolites	may	 arise	 from	 alterations	 in	 gut	 microbiota	 in	 a	 range	 of	 disorders	 such	 as	obesity,	9	 impaired	glucose	tolerance	10	and	liver	disease,	11	suggesting	that	the	usual	symbiotic	relationship	between	gut	microbiota	and	host	may	turn	dysbiotic	in	these	conditions,	allowing	gut	flora	to	exacerbate	disease.	In	addition,	the	gut	microbiome	 has	 been	 implicated	 as	 a	 source	 of	 pathogenic	 mediators	 in	 the	context	of	CKD.	12	In	this	clinical	setting,	compounds	derived	from	dysbiotic	gut	bacteria	 are	 absorbed	 into	 the	 circulation	 and	 accumulate	 due	 to	 reduced	excretion	 by	 the	 kidney.	 Blood	 levels	 of	 some	 of	 these	 compounds	 have	 been	shown	to	correlate	with	dysregulated	immunity,	CV	disease	burden	and	decline	of	kidney	function.	12	Over	the	last	five	years,	the	role	of	trimethlyamine-N-oxide	
(TMAO)	as	a	gut-derived	metabolite	mediating	CV	disease	pathogenesis	has	been	under	particularly	intense	scrutiny.			
Trimethlyamine-N-oxide	biology	TMAO	has	 two	well-described	 biological	 functions.	 Firstly,	 this	 oxidized	 amine	promotes	 bacterial	 growth	 by	 acting	 as	 an	 electron	 acceptor	 during	 anaerobic	respiration.	 13	Gaseous	 trimethylamine	(TMA)	 is	produced	as	a	by-product	and	has	a	characteristic	strong	malodor	facilitating	its	use	as	an	indicator	of	spoilage	by	 the	 fish	 industry.	 13	 Secondly,	 TMAO	 plays	 a	 role	 in	 preserving	 protein	structure	 and	 function	 in	vivo.	Marine	 animals	 experience	 large	 fluctuations	 in	urea	concentration,	salinity	and	hydrostatic	pressure	that	can	denature	proteins.	To	 preserve	 protein	 conformation	 and	 function,	 TMAO	 interrupts	 these	destabilizing	hydrophobic	interactions	by	serving	as	a	chemical	chaperone.	14,15	Despite	 evidence	 of	 these	 biological	 activities,	 no	 clear	 physiological	 role	 for	TMAO	has	 so	 far	 been	 confirmed	 in	 humans.	 For	 example,	 although	osmolytes	such	 as	 TMAO	may	 stabilize	 protein	 structure	 and	 function	 in	 human	 cells	 in	
vitro	15	there	remains	a	lack	of	data	to	support	this	function	in	vivo.		
TMAO	Metabolism	in	Mammals	Mammalian	 TMAO	 production	 is	 a	 two-step	 process	 (Figure	 1).	 The	 first	 step	involves	 gut	 bacteria	 that	 metabolize	 TMA-containing	 substrates	 such	 as	phosphatidylcholine	(lecithin),	choline,	betaine	and	L-carnitine	(found	in	dietary	red	 meat,	 fish	 and	 eggs).	 Experimental	 studies	 dating	 back	 to	 the	 mid	 1900s	demonstrated	 increases	 in	 urinary	 trimethlyamine-N-oxide	 (TMAO)	 after	feeding	 rats	 dietary	 choline,	 but	 not	 when	 the	 same	 dose	 was	 injected	 intra-peritoneally.	16	Gut	flora	eradication	with	antibiotic	treatment	in	both	mice	and	human	 subjects	 prevented	 TMAO	 production,	 but	 when	 gut	 bacteria	 were	allowed	 to	 repopulate,	 TMAO-generating	 capacity	 was	 restored.	 17,18	 In	 the	second	 step,	 bacterially	 cleaved	 gaseous	 TMA	 is	 rapidly	 absorbed	 into	 the	circulation	 and	 oxidized	 by	 the	 liver	 enzyme	 flavin	monooxygenase	 isoform	 3	(FMO3)	to	form	TMAO.	19	(Figure	1).	Unlike	certain	 species	of	bacteria	and	 fish,	mammals	 lack	 the	enzymatic	capacity	to	further	reduce	or	demethylate	TMAO	and	>95%	of	total	body	TMAO	
is	excreted	unchanged	by	the	kidney	20	through	glomerular	filtration	and	tubular	secretion,	the	latter	accounting	for	at	least	half	of	all	TMAO	excreted	in	the	urine.	21	 Consistent	 with	 this,	 patients	 commenced	 on	 drugs	 known	 to	 modulate	tubular	 function,	 such	 as	 anti-retroviral	 protease	 inhibitors	 22	 and	 calcineurin	inhibitors	23,	may	exhibit	elevations	in	plasma	TMAO	or	reduced	urinary	TMAO	clearance.	22,23	Potential	cell	membrane	transporters	for	TMAO	uptake	and	efflux	have	 been	 identified.	 Overexpression	 of	 organic	 cation	 transporter	 2	 (Oct2)	 in	HeLa	cells	results	in	a	3-fold	increase	in	intracellular	TMAO	concentration,	whilst	
in	vivo,	 global	Oct1/2	 gene	deletion	 in	mice	 is	 associated	with	 a	 2-fold	 greater	plasma	 TMAO	 concentration	 when	 compared	 to	 wild-type	 controls.	 24	Provisional	 in	 vitro	 data	 suggest	 that	 multiple	 efflux	 transporters	 of	 the	 ATP-binding	 cassette	 (ABC)	 family	 (variably	 expressed	 in	 liver,	 kidney	 and	 gut	epithelia)	may	also	play	a	role	in	TMAO	efflux	and	hence	excretion.	24	
	
Figure	1.	The	Mammalian	TMAO	Pathway.	Gut	 bacteria	 metabolize	 TMA-containing	 substrates	 such	 as	 phosphatidylcholine	 (lecithin),	choline,	 betaine	 and	 L-carnitine	 (found	 in	 dietary	 red	meat,	 fish	 and	 eggs).	 Bacterially	 cleaved	gaseous	 TMA	 is	 rapidly	 absorbed	 into	 the	 circulation	 and	 oxidized	 by	 the	 liver	 enzyme	 flavin	monooxygenase	isoform	3	(FMO3)	to	form	TMAO.	Mammals	cannot	metabolize	TMAO	and	>95%	
of	 total	 body	 TMAO	 is	 excreted	 unchanged	 by	 the	 kidney	 through	 glomerular	 filtration	 and	tubular	secretion.		
TMAO	as	a	mediator	of	CV	disease:	Clinical	Data	The	 first	 human	 study	 to	 implicate	 TMAO	 as	 a	 mediator	 of	 CV	 disease	 used	unbiased	 plasma	 metabolomic	 screening	 to	 identify	 three	 metabolites	 of	phosphatidylcholine;	 choline,	 betaine	 and	 TMAO	 that	 independently	 predicted	incident	CV	events	(heart	attack,	stroke	and	CV	death)	in	1876	subjects	referred	for	 cardiac	disease	 evaluation	over	 a	 3-year	 follow-up	period.	 17	 Subsequently,	having	extended	their	cohort	to	2595	subjects,	these	investigators	demonstrated	that	 plasma	 levels	 of	 L-carnitine,	 an	 alternative	 TMAO	 precursor,	 was	 also	predictive	 of	 CV	 events	 when	 raised	 in	 association	 with	 TMAO,	 over	 a	 3	 year	follow-up	period.	18	Two	other	observational	studies	linked	plasma	TMAO	levels	to	severity	of	heart	failure.	Both	a	Norwegian	study	of	155	heart	failure	patients	25	and	a	North	American	study	of	112	patients	26	reported	associations	between	higher	plasma	TMAO,	symptom	severity	and	risk	of	all-cause	mortality	or	heart	transplantation	over	a	5-year	follow-up	period.	25,26	 Importantly,	 increased	age,	previous	 myocardial	 infarction	 25	 and	 reduced	 kidney	 function	 assessed	 by	estimated	 glomerular	 filtration	 rate	 (eGFR)	 strongly	 predicted	 blood	 TMAO	levels.		
	 Despite	these	initial	findings,	the	association	between	blood	TMAO	levels	and	 CV	 disease	 has	 not	 been	 consistent	 in	 all	 population	 studies	 to	 date.	 In	 a	North	American	 study	of	817	mixed	 race	healthy	volunteers	aged	33-45	years,	plasma	 TMAO	 levels	 were	 not	 associated	 with	 incident	 coronary	 artery	calcification	 assessed	 by	 computed	 tomography	 or	 coronary	 artery	 intimal-medial	wall	thickness	assessed	by	ultrasound	over	a	10-year	follow-up	period.	27		A	Chinese	study	reported	that	although	distinct	profiles	of	gut	flora	were	associated	 with	 cerebrovascular	 disease	 severity,	 TMAO	 concentrations	 were	actually	 lower	 in	 patients	 with	 prevalent	 cerebrovascular	 disease	 when	compared	 to	 asymptomatic	 controls	 and	 were	 not	 associated	 with	 increased	intima-media	carotid	artery	thickness	or	the	presence	of	atherosclerotic	plaques.	28	Similarly,	a	European	study	of	339	patients	undergoing	coronary	angiography	
found	 no	 association	 between	 plasma	 TMAO	 and	 prevalent	 coronary	 artery	disease	or	incident	events	over	an	8-year	follow-up	period.	29	Infection	with	HIV	carries	a	greater	risk	of	developing	CV	disease.	A	study	comparing	 coronary	 calcium	 scores	 in	 HIV-infected	 patients	 and	 non-infected	controls	 found	 that	 TMA	 but	 not	 TMAO	 concentrations	 correlated	with	 higher	plaque	 burden,	 but	 only	 in	 the	 HIV-positive	 group.	 30	 In	 another	 HIV	 cohort,	higher	plasma	TMAO	levels	were	associated	with	advanced	age,	reduced	kidney	function	 and	 use	 of	 protease	 inhibitors,	 but	 not	 with	 coronary	 artery	 calcium	scores	or	myocardial	infarction.22		Study	 of	 humans	 with	 variants	 of	 the	 FMO3	 gene	 could	 provide	opportunities	to	assess	the	 impact	of	reduced	TMAO	production	on	CV	disease.	Trimethylaminuria,	 or	 Fish	 Odor	 Syndrome,	 results	 from	 a	 rare	 FMO3	 gene	variant	 with	 markedly	 diminished	 capacity	 for	 oxidizing	 TMA	 into	 TMAO.	Accumulation	of	TMA	gives	a	strong	fishy	odor	to	the	breath,	sweat,	and	urine.	31	However,	 despite	 extremely	 low	 TMAO	 levels,	 there	 are	 no	 studies	 suggesting	that	individuals	with	this	rare	condition	are	protected	from	CV	disease.		In	terms	of	 more	 common	 FMO	 gene	 variants,	 a	 large	 consortium	 genome-wide	association	 study	 of	 ~22,000	 coronary	 artery	 disease	 patients	 with	 ~65,000	control	 subjects	 did	 not	 reveal	 an	 association	 between	 388	 FMO	 gene	polymorphisms	 and	 coronary	 artery	 disease.	 32	 In	 a	 separate	 cohort,	 no	association	was	 identified	 between	471	 FMO	gene	 polymorphisms	 and	plasma	TMAO	levels	in	3865	subjects	referred	for	cardiac	evaluation.	32		These	 apparently	 conflicting	 data	 linking	 blood	 TMAO	 levels	 with	cardiovascular	 disease	 risk	 are	 likely	 to	 have	 resulted	 from	 a	 combination	 of	issues	 including	differences	 in	 study	methodology,	 diet,	 ethnicity,	 environment	and	prevalent	patterns	of	gut	microbiome	composition	in	study	subjects.	Liquid	chromatography	 tandem	mass	 spectrometry	 (LC-MS/MS)	 is	 frequently	 used	 to	measure	 plasma	 TMAO	 and	 has	 high	 sensitivity	 and	 specificity.	 Despite	 this,	reported	 inter-	 and	 intra-individual	 ranges	 of	 TMAO	 concentrations	 are	 wide.	For	 example,	 fasting	 plasma	 TMAO	 concentrations	 in	 349	 healthy	 North	American	subjects	ranged	between	0.73	-	126uM.	33	A	New	Zealand	study	of	243	overweight	 individuals	 with	 type	 2	 diabetes	 but	 no	 significant	 kidney	 disease	(eGFR>60	mL/min/1.73m2),	 revealed	 high	 intra-individual	 variability	 amongst	
four	 samples	 taken	 over	 2-years.	 Log-normal	 reference	 change	 values	 ranged	from	 403%	 to	 -80%	 in	 plasma,	 whilst	 by	 comparison,	 an	 alternative	 TMA-substrate	betaine	ranged	from	54%	to	-35%.	34	Such	inter-	and	intra-individual	variability	 of	 plasma	 TMAO	 could	 limit	 its	 use	 as	 a	 reliable	 biomarker	 and	provides	an	explanation	as	to	why	reports	of	TMAO	and	disease	associations	can	differ.	 Additional	 explanations	 for	 discrepant	 data	 include	 the	 fact	 that	 TMAO	levels	in	co-morbid	individuals	are	determined	by	a	variety	of	intrinsically	linked	pathogenic	 factors	 including	 an	 unhealthy	 diet,	 a	 dysbiotic	 gut	 microbiome,	dysregulated	 FMO3	 activity	 and	 perhaps	 most	 importantly,	 reduced	 clearance	via	the	kidneys.			
TMAO	as	a	Mediator	of	CV	Disease:	Experimental	Data	Experimental	data	 suggest	 that	TMAO	may	directly	enhance	atherogenesis	and	contribute	 to	 CV	 events	 via	 dysregulation	 of	 lipid	 handling	 and	 macrophage	function	as	well	as	directly	causing	vascular	inflammation	and	platelet	activation	leading	 to	 thrombosis	 (Figure	 2).	 Atherosclerosis-prone	 apolipoprotein	 E	knockout	mice	(ApoE-/-)	fed	supplemental	choline	or	TMAO	developed	elevated	plasma	 TMAO	 levels,	 larger	 aortic	 atherosclerotic	 plaques	 with	 enriched	macrophage	 content	 as	 compared	 to	 wild	 type,	 although	 these	 effects	 were	prevented	by	pre-treatment	with	antibiotics.	17	Elevated	TMAO	in	ApoE-/-	mice	also	 reduces	 reverse	 cholesterol	 transport	 18	 and	 in	 wild-type	 mice,	 causes	peritoneal	 macrophages	 to	 express	 higher	 scavenger	 receptor	 proteins	 (CD36	and	 SR-A1)	 and	 become	 cholesterol-laden	 foam	 cells.	 17	 Furthermore,	 raising	plasma	 TMAO	 in	 mice	 fed	 another	 substrate,	 L-carnitine,	 is	 associated	 with	decreased	liver	mRNA	expression	of	the	bile	acid	synthetic	enzymes	Cyp7a1	and	Cyp27a1,	indicating	reduced	ability	to	eliminate	bile-acid	cholesterol.18	Several	 pro-inflammatory	mediators	 including	 Cyclo-oxygenase-2	 (COX-2),	E-Selectin	and	Intracellular	Adhesion	Molecule-1	(ICAM-1)	were	upregulated	in	the	aortic	tissue	of	low-density	lipoprotein	receptor	knock-out	(LDLr-/-)	mice	receiving	 dietary	 choline	 or	 intraperitoneal	 TMAO.35	 In	 vitro,	 TMAO	 enhanced	leucocyte	 adhesion	 to	 endothelial	 cells	 in	 an	 NF-κB-dependent	 manner.	 35	Furthermore,	 enhanced	 platelet	 activation	 and	 adhesion	 has	 been	 observed	
following	 intraperitoneal	 TMAO	 injections	 in	 an	 in	 vivo	 carotid	 artery	 injury	model.	36		
	
Figure	2.	Pathogenic	Mechanisms	of	TMAO	contributing	to	CV	and	Kidney	Disease.	Experimental	data	suggest	that	TMAO	may	directly	enhance	atherogenesis	and	contribute	to	CV	events	via	 dysregulation	of	 lipid	handling	and	macrophage	 function	as	well	 as	directly	 causing	vascular	inflammation	and	platelet	activation	leading	to	thrombosis.				 What	is	not	clear	is	how	TMAO	mediates	these	cellular	responses	because	no	cell	surface	receptors	have	been	 identified.	 	One	potential	mechanism	is	 the	protein-stabilizing	 effect	 of	 TMAO,	 which	 provides	 protection	 against	physiological	 stress.	 However,	 this	 action	 may	 not	 necessarily	 be	 beneficial.	Under	certain	circumstances	in	mammals,	TMAO	may	reduce	protein	function	or	limit	 degradation	 of	 key	 enzymes	 or	 signaling	 proteins	 with	 potentially	deleterious	downstream	effects.	15	
	
TMAO	and	CV	Risk	in	Chronic	Kidney	Disease	As	 kidney	 function	 declines	 from	 stage	 3a	 (eGFR	 45-60	mL/min/1.73m2)	 and	beyond,	 circulating	 TMAO	 concentrations	 not	 only	 rise	 but	 also	 become	increasingly	 variable,	 one	 study	 reporting	 median	 concentrations	 of	 3.3	 μM	(inter-quartile	 range	 3.1-6.0	 μM)	 in	 healthy	 volunteers	 versus	 94.4	 μM	 (inter-
quartile	 range	 54.8-133	 μM)	 in	 people	with	 end-stage	 kidney	 disease.	 37	 As	 in	non-CKD	 populations,	 elevated	 TMAO	 levels	 have	 been	 reported	 to	 predict	 CV	events	and	mortality	in	cohorts	with	mild	to	moderately	severe	CKD	(stages	3-4)	even	after	correction	for	kidney	function	and	traditional	CV	risk	factors	such	as	age,	blood	pressure	and	lipid	status.	37,38	A	1.9-fold	 increased	risk	of	5-year	all-cause	mortality	was	 reported	 in	 stage	3	CKD	subjects	with	TMAO	 levels	 in	 the	highest	 quartile	 as	 compared	 to	 those	 in	 the	 lowest	 quartile.	 38	 In	people	with	CKD	stage	3-4,	blood	TMAO	concentrations	independently	correlated	with	both	coronary	 artery	 disease	 severity	 score	 (assessed	 by	 quantitative	 angiography)	and	mortality	when	used	as	 a	 continuous	variable,	 but	 this	was	not	 significant	when	 tested	 across	 TMAO	 tertiles.	 37	 Following	 kidney	 transplantation,	 TMAO	levels	 fall	 towards	 normal,	 leading	 to	 speculation	 that	 improved	 clearance	 of	TMAO	may	 at	 least	 in	 part	 account	 for	 reduced	 risk	 of	 CV	 observed	 in	 kidney	allograft	 recipients.	 37	 Finally,	 in	 a	 large	 study	 of	 over	 2500	 Canadian	 patients	with	 CKD,	 plasma	 TMAO	 independently	 predicted	 CV	 events	 over	 a	 3-year	follow-up	period	in	stage	3,	but	not	in	stage	4	(in	which	TMAO	was	much	more	variable).39	Some	thought	is	required	before	interpreting	these	data	as	evidence	of	an	independent	association	between	TMAO	and	CV	disease	in	renal	impairment,	let	alone	 one	 of	 causation.	 Statistical	 correction	 for	 reduced	 renal	 clearance	 of	TMAO	using	creatinine	or	cystatin	C	-based	measures	of	eGFR	does	not	account	for	 tubular	 function,	 which	 has	 an	 impact	 on	 excretion	 of	 TMAO.	 Tubular	function	 can	 be	 highly	 variable	 at	 any	 given	 eGFR	 and	 often	 depends	 on	 the	underlying	CKD	aetiology.	40	In	addition	to	the	key	confounding	issue	of	reduced	renal	TMAO	clearance,	gut-related	factors	specific	to	CKD	are	likely	to	contribute	to	elevated	blood	TMAO	levels.	Gut	microbiome	subpopulation	composition	may	shift	from	symbiotic	to	dysbiotic	under	the	influence	of	“uraemic”	factors	such	as	gut	oedema,	reduced	transit	time,	anorexia	or	adherence	to	a	low	phosphorus	or	potassium	diet	along	with	oral	phosphate	binders	and	iron	replacement.	12	
TMAO	and	CV	Risk	in	Hemodialysis	Cohorts	Hemodialysis	clears	TMAO	at	a	rate	similar	 to	creatinine,	with	re-accumulation	to	 plasma	 concentrations	 of	 approximately	 100μM	 before	 the	 subsequent	
dialysis	 session.	 21,37	 Studies	 in	 this	 population	 do	 not	 indicate	 a	 consistent	predictive	 value	 of	 plasma	 TMAO	 levels	 for	 CV	 disease	 risk.	 A	 recent	 North	American	 study	 of	 1232	 mixed	 race	 hemodialysis	 patients	 reported	 a	 4-fold	higher	risk	of	cardiac	mortality	in	white	patients	in	the	highest	quintile	of	plasma	TMAO	(>135μM)	compared	to	their	black	counterparts	over	a	median	follow-up	of	2.3-years.	41	Importantly,	the	white	subgroup	contained	more	males	and	had	increased	 co-morbidity	 scores,	 more	 prevalent	 gastrointestinal	 disease	 and	better	 residual	 kidney	 function	 than	 black	 participants,	 which	 potentially	confounded	results.	In	a	cohort	of	235	hemodialysis	patients,	no	association	was	found	 between	 blood	 TMAO	 concentrations	 and	 cardiovascular	 mortality,	 but	TMAO	did	 correlate	with	 serum	albumin,	 creatinine	and	 inversely	with	CRP.	 42	An	attenuated	or	even	reverse	association	between	traditional	disease	markers	such	as	high	blood	pressure	or	blood	 cholesterol	 and	 cardiovascular	outcomes	has	 previously	 been	 reported	 in	 the	 hemodialysis	 population,	 likely	 due	 to	confounding	 by	 comorbidity	 3,4	 and	 TMAO	 may	 be	 subject	 to	 the	 same	phenomenon.	 For	 example,	 much	 like	 albumin,	 lower	 TMAO	 levels	 in	 some	hemodialysis	patients	could	reflect	poor	nutritional	and	overall	health	status.	42	Because	 of	 such	 confounding,	 interventional	 studies	 are	 likely	 to	 be	 the	 only	reliable	method	 to	 test	 the	hypothesis	 that	TMAO	contributes	 to	CV	disease	 in	the	context	of	CKD.	
	
Potential	treatment	strategies	to	reduce	TMAO	exposure	Besides	renal	clearance,	current	evidence	 indicates	that	dietary	 intake	and	gut-microbial	metabolism	are	the	strongest	determinants	of	plasma	TMAO	levels	and	hence	hold	the	most	promise	for	therapeutic	intervention.	Whilst	genetic	knock-down	of	FMO3	protected	against	atherosclerosis	 in	atherosclerotic-prone	mice,	43	 human	 genome-wide	 association	 data	 suggest	 that	 single	 genes	 contribute	little	 to	plasma	TMAO	concentrations	 32	and	 the	wide	range	of	other	metabolic	functions	served	by	FMO	enzymes	mean	that	pharmacological	FMO3	inhibition	is	unlikely	to	provide	overall	benefit.		
Dietary	approaches	
Fish	 and	 red	meat	 contain	 high	 concentrations	 of	 TMA-precursors	 and	 TMAO,	but	 avoiding	 dietary	 fish	 in	 order	 to	 reduce	 CV	 disease	 risk	 is	 a	 strategy	 not	supported	by	current	evidence.	Fish	ingestion	can	elevate	TMAO	excretion	more	than	 20-times	 higher	 when	 compared	 to	 alternative	 diets	 16	 but	 despite	 this,	higher	 consumption	 of	 fish	 has	 long	 been	 associated	 with	 protection	 against	ischaemic	heart	disease.	44	Dietary	L-carnitine	from	red	meat	represents	a	source	of	TMAO	and	could	thus	potentiate	CV	disease.	18	This	conflicts	with	a	reported	CV	protective	effect	of	L-carnitine	supplementation,	which	is	itself	inconsistent	between	populations.	A	meta-analysis	of	13	 controlled	 trials	using	L-carnitine	 supplementation	 (oral	or	intravenous)	following	acute	myocardial	infarction	reported	a	27%	reduction	in	mortality	compared	with	placebo	or	control.	45	In	a	meta-analysis	of	49	trials	conducted	 in	 end-stage	 kidney	 disease	 patients	 receiving	 hemodialysis	 and	 L-carnitine	supplementation	(37	using	intravenous	and	12	oral	administration),	no	such	 mortality	 benefit	 was	 found	 although	 serum	 low-density-lipoproteins	(LDLs)	and	C-reactive	protein	(CRP)	were	both	reduced.	46	L-carnitine	undergoes	gut	microbial	conversion	to	TMA	and	intravenous	administration	bypasses	this,	thereby	providing	a	means	to	test	the	protective	effects	of	L-carnitine,	whilst	not	affecting	 TMAO	 concentrations.	 In	 the	 above	 meta-analysis,	 intravenous	 L-carnitine	 reduced	 serum	 cholesterol	 and	 hematocrit	 when	 compared	 to	 oral	supplementation46.	 Consistent	 with	 this,	 a	 small	 crossover	 study	 showed	improved	 lipid	 profiles	 (reduced	 serum	 fatty	 acids	 and	 increased	 high-density	lipoproteins)	 after	 switching	 from	 oral	 to	 intravenous	 L-carnitine	 but	 it	 is	unclear	whether	 this	effect	was	 related	 to	 increased	bioavailability	 rather	 than	avoidance	 of	 TMAO	production,	which	was	not	 reported.	Direct	 comparison	 of	the	 long-term	 effects	 of	 oral	 versus	 intravenous	 L-carnitine	 supplementation	would	likely	be	informative	but	have	not	yet	been	tested	in	large	clinical	trials.	In	addition	to	being	a	direct	source	of	TMA-precursors,	a	diet	rich	in	fish	and	 red	 meat	 changes	 the	 composition	 of	 gut	 flora	 favoring	 TMA-forming	bacteria	such	as	Clostridia	and	Prevotella,	18	thereby	potentiating	elevated	blood	TMAO	 levels.	 Whilst	 outright	 avoidance	 of	 meat	 and	 fish	 is	 not	 necessarily	beneficial,	the	potential	for	the	diet	to	alter	gut	flora	indicates	to	an	opportunity	
to	recover	a	symbiotic	gut	microbiome	or	at	least	reduce	the	component	of	TMA-producing	bacteria.		
Therapeutic	Manipulation	of	the	Gut	Microbiome	Prebiotics	 (eg.	 oligosaccharides)	 are	 indigestible	 food	 additives	 that	 promote	growth	of	beneficial	bacteria	subtypes	whilst	limiting	proliferation	of	pathogenic	bacteria	 populations.	 Resveratrol	 is	 a	 naturally	 occurring	 polyphenol	 found	 in	grapes	and	berries	 that	when	 fed	 to	ApoE-/-	mice,	 increased	gut	Lactobacillus,	decreased	 plasma	 TMAO	 levels	 and	 attenuated	 aortic	 atherosclerosis.	 47	Probiotics	 are	 live	 microorganisms	 (eg.	 Lactobacilli,	 Streptococci)	 that	 when	ingested	can	alter	the	pattern	of	resident	gut	flora.	A	small	randomized,	double-blinded,	placebo-controlled	trial	in	37	stage	4-5	CKD	patients	demonstrated	that	a	 combination	 of	 pre-	 and	 probiotics	 altered	 gut	 microbiota	 composition	 and	reduced	 plasma	 concentrations	 of	 gut-derived	 uraemic	 metabolite	 p-cresyl	sulfate	 48	 providing	 support	 for	 the	 use	 of	 similar	 agents	 in	 CKD	 patients	 to	reduce	gut	bacteria-derived	TMAO.	Alternative	 strategies	 to	 reduce	 absorption	 of	 gut-derived	 TMA	 include	structural	choline	analogues	such	as	3,3-dimethyl-1-butanol	(DMB),	which	have	been	 shown	 to	 reduce	plasma	TMAO	 levels	 and	prevent	macrophage	 foam	cell	formation	 in	 APOE-/-	 mice,	 but	 have	 not	 yet	 been	 tested	 in	 humans.	 49	 Oral	meldonium,	 a	 synthetic	 structural	 analogue	 of	 L-carnitine	 precursor	 γ-butyrobetaine,	 limited	 elevations	 in	 plasma	 TMAO	 after	 a	 fish-rich	 diet	 and	increased	 urinary	 TMAO	 excretion	 by	 35%	 in	 human	 test	 subjects.50	 It	 is	 not	clear	if	this	effect	was	due	to	inhibition	of	reabsorption	or	enhanced	secretion	of	TMAO	 by	 the	 tubule.	 If	 a	 tubular	 TMAO	 transporter	 is	 confirmed,	 targeted	therapeutic	strategies	to	enhance	urinary	TMAO	clearance	may	be	feasible.		
Conclusion	With	 the	 available	 data	 it	 is	 difficult	 to	make	 a	 compelling	 case	 for	 the	 use	 of	TMAO	 in	 clinical	 practice	 either	 as	 a	 biomarker	 or	 a	 therapeutic	 target	 in	 any	patient	 population.	 Although	 elevated	 circulating	 plasma	 TMAO	 levels	 are	associated	 with	 an	 increased	 risk	 of	 CV	 disease	 in	 some	 (including	 CKD)	populations,	the	available	data	are	inconsistent	across	observational	studies.	It	is	
therefore	unclear	whether	TMAO	contributes	to	CV	disease	in	CKD	patients	or	it	is	simply	yet	another	marker	of	reduced	renal	clearance.	To	establish	a	role	for	TMAO	in	CKD-associated	cardiovascular	disease,	large-scale	interventional	trials	are	 required	 using	 TMAO	 reduction	 strategies	 with	 assessment	 of	 clinical	endpoints	 relevant	 to	 the	CV	diseases	prevalent	 in	 this	population.	 If	 therapies	that	 modify	 the	 gut	 microbiome	 can	 be	 developed	 with	 tolerable	 side	 effect	profiles,	 such	 studies	 may	 become	 possible.	 In	 our	 view,	 more	 compelling	observational	 and	mechanistic	 data	 are	 required	 before	 significant	 amounts	 of	time	and	money	are	invested	in	large	clinical	trials	targeting	TMAO	reduction	in	CKD	patients.			
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